MeiraGTx Holdings plc
Biotechnology, Genetics, Health Care
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, and a transformative gene regulation platform technology that allows precise, dose-responsive control of gen
Key facts
- Employees
- Unknown
- Industries
- Biotechnology, Genetics, Health Care
- Status
- Public (MGTX)
- Website
- meiragtx.com
- Company page
Recent activity at MeiraGTx Holdings plc
- : MeiraGTx Appoints Alan M. Sebulsky as Class I Director
- : SEC 8-K (5.02): On September 22, 2026, MeiraGTx Holdings plc's Board of Directors appointed Alan M. Sebulsky as a Class I director, effective September 23, 2026. His term will last until the Company's 2028 annual meeting of shareholders. Mr. Sebulsky will also serve on the Science and Technology Committee, following recommendation by the Company’s senior management. This appointment is strategic as it strengthens the company's governance and aligns with its focus on scientific innovations.
- : MeiraGTx acquires bota-vec from Johnson & Johnson
- : MeiraGTx Enters Strategic Collaboration Agreement with Eli Lilly
- : SEC 8-K (1.01): On November 7, 2025, MeiraGTx Holdings plc, through its subsidiaries MeiraGTx Ocular UK Limited, MeiraGTx Limited, and MeiraGTx UK II Limited, entered into a strategic collaboration and license agreement with Eli Lilly and Company. This Collaboration Agreement grants Lilly exclusive, worldwide rights from MeiraGTx to research, develop, and commercialize genetic medicines specifically focused on ophthalmology. This partnership is significant as it enhances MeiraGTx's strategic position in the field of genetic therapies, potentially leading to advancements in treatment options for eye diseases. The financial terms and other conditions of the collaboration have not been disclosed in the summary.
- : Meiragtx Announces Financing Agreement With Perceptive Advisors For Up To $100 Million Secured By Manufacturing Facilities
MeiraGTx Holdings plc funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2022 | Debt Financing | Undisclosed |
Leadership
- Alan M. Sebulsky, Director
- Oliver Peyer, Automation Scientist
- Sarah Jeeves, Senior Human Resources Business Partner
Verified email and direct lines for MeiraGTx Holdings plc’s decision-makers are on Fundz. See plans
Employee benefit plans
MeiraGTx Holdings plc files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
MeiraGTx Holdings plc in the news
- Can MeiraGTx Holdings PLC (MGTX) Stock Double? Cash Runway Offers a Hint - Yahoo Finance (May 20, 2026)
- Goldman Sachs starts MeiraGTx coverage with a USD 16 target for MeiraGTx stock - AD HOC NEWS (Oct 01, 2026)
- MeiraGTx Holdings plc ($MGTX) President and CEO 2025 Pay Revealed - Quiver Quantitative (May 01, 2026)
- H.C. Wainwright reiterates MeiraGTx stock rating on financing deal - Investing.com (Jul 08, 2026)
- MeiraGTx acquires J&J's XLRP investigational therapy - Glance by Eyes On Eyecare (Apr 24, 2026)
- MeiraGTx reports Q1 2026 results: $0.3M revenue, $46.3M net loss, $73.8M cash - tradingview.com (May 14, 2026)
- Here's What Analysts Are Forecasting For MeiraGTx Holdings plc (NASDAQ:MGTX) After Its First-Quarter Results - Yahoo Finance (May 17, 2026)
- MeiraGTx Holdings PLC (MGTX) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance (Mar 26, 2026)
Companies similar to MeiraGTx Holdings plc
- Gaomei Gene · Biotechnology, Genetics, Health Care, Therapeutics
- Genmab · Biotechnology, Genetics, Health Care, Therapeutics
- Akouos, Inc. · Biotechnology, Genetics, Health Care, Therapeutics
- Florida Biotechnologies · Biotechnology, Genetics, Health Care, Therapeutics
- BioMarin · Biotechnology, Genetics, Health Care, Therapeutics
About MeiraGTx Holdings plc: questions and answers
What does MeiraGTx Holdings plc do?
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, and a transformative gene regulation platform technology that allows precise, dose-responsive control of gen
Has MeiraGTx Holdings plc raised funding?
Yes. Fundz has recorded 1 funding event for MeiraGTx Holdings plc. The most recent, Debt Financing of Undisclosed, was in Aug 2022.
What is the latest news on MeiraGTx Holdings plc?
On Sep 23, 2026, MeiraGTx Appoints Alan M. Sebulsky as Class I Director
Is MeiraGTx Holdings plc a public company?
Yes. MeiraGTx Holdings plc is publicly traded under the ticker MGTX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy